SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several pharmaceutical and drug discovery companies. Partnerships and collaborations are imminent. Why? -because Lunai Bioworks operates a closed loop AI system that is truly disruptive (and complementary) to current discovery platforms and that turns complex biology into real-world action in several ways with less cash burn and new revenue streams. Our Augusta platform starts with real biolo

AI-driven analysis of Phase 2 survival and progression data aims to identify high-benefit patient subgroups and optimize future registrational trial strategy SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ:LNAI), an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a clinical-stage partner to analyze data from a randomized Phase 2 metastatic colorectal cancer trial. The objective is to define biologically meaningful patient subgroups that may benefit most from the investigational therapy. U

Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents in real time. SACRAMENTO, Calif., Jan. 27, 2026 /PRNewswire/ -- As global attention intensifies around the dual-use risks of advanced artificial intelligence in chemistry and biology, Lunai Bioworks (NASDAQ:LNAI) today announced the deployment of Sentinel™, a transformer-based AI safeguard designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents. Built on Lunai's expansive molecular AI platform and strengthened by

AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder Program SACRAMENTO, Calif. , Jan. 26, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ:LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal. Using high-throughput vertebrate screening, the company identified distinct, reproducible neurobehavioral phenotypes that are only partially addressed by currently approved therapies, highlighting previously underexplored biological mechanisms with strong translation

SACRAMENTO, Calif., Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ:LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets that may accelerate proof-of-concept programs, derisk therapeutic development, and enable strategic co-development partnerships in a growing $13 billion market. Using its proprietary Augusta Platform, Lunai Bioworks' wholly owned subsidiary BioSymetrics integrated large-scale proteomic data from the Parkinson'

Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable therapies for aggressive cancers SACRAMENTO, Calif., Nov. 25, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ:LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models. This mi

Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 5, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ:LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its next-generation immune cell therapy led to complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. The study was published in a new Brief Report in Vaccines on November 2, 2025. The peer-reviewed Brief Report details the development of a s

8-K - Lunai Bioworks Inc. (0001527728) (Filer)

424B5 - Lunai Bioworks Inc. (0001527728) (Filer)

8-K - Lunai Bioworks Inc. (0001527728) (Filer)